Clinical trials
Metastatic Colorectal Cancer clinical trials
Below are recruiting metastatic colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 540 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06411600RecruitingPhase 2
Combination therapy for BRAF-mutated colorectal cancer
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
BarcelonaAges 18 years+ - NCT06412198RecruitingPhase 1/Phase 2
Combination Drug Study for KRAS G12C Colorectal Cancer
This trial tests three drugs (adagrasib, cetuximab, cemiplimab) together for colorectal cancer with a KRAS G12C mutation. The goal is to see if this combination shrinks tumors or slows cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06425133RecruitingPhase 2
Regorafenib plus low-dose chemo for advanced colorectal cancer
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
AuxerreAges 18 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06441565RecruitingPhase 2/Phase 3
Fruquintinib with or without liver-directed chemo for advanced colorectal cancer
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
Guangzhou, GuangdongAges 18–75 - NCT06449989Recruiting
Comparing genetics of colorectal cancer and its brain spread
This study compares the genetics of the original colorectal cancer with the cancer that has spread to the brain. It aims to understand how the tumor changes when it metastasizes, which may help guide future treatments.
Moscow, MoscowAges 18 years+ - NCT06449937Recruiting
Local liver treatment for colorectal cancer that has spread
This trial tests whether treating liver tumors with surgery or ablation can help people whose colorectal cancer has spread to the liver and other organs. It may be an option if you've had only 1 or 2 types of chemotherapy and your non-liver metastases are stable.
Chuzhou, AnhuiAges 18–80 - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06149481RecruitingPhase 1/Phase 2
STAR15 immunotherapy for metastatic colorectal cancer
This trial tests a combination of four drugs (SX-682, TriAdeno vaccine, retifanlimab, and N-803) to see if they can help people with colorectal cancer that has spread. It may be an option if you have already tried at least two standard treatments or cannot take them.
Bethesda, MarylandAges 18–120 - NCT06487377RecruitingPhase 1
IX001 TCR-T for advanced KRAS-mutated pancreatic and colorectal cancer
This trial tests a new treatment called IX001 TCR-T, which uses your own immune cells to target cancer cells with a specific KRAS mutation. It's for people with advanced pancreatic or colorectal cancer who have run out of standard options.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06493760RecruitingPhase 2
Testing a new drug for advanced colorectal cancer
This trial tests a new drug called SSGJ-707 for people with colorectal cancer that has spread. It aims to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06500052RecruitingPhase 1
Study of BL-M17D1 for HER2-positive or low-expression digestive tract and other solid tumors
This trial tests a new drug called BL-M17D1 for people with advanced or metastatic HER2-positive or low-expression gastrointestinal cancer and other solid tumors. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06509126RecruitingPhase 3
Panitumumab with Chemo: Continuous or Intermittent for Advanced CRC
This trial compares giving panitumumab plus FOLFIRI (two chemotherapy drugs) either continuously or with breaks, as a first treatment for left-sided colorectal cancer that has spread. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and haven't had treatments for advanced disease before.
NaplesAges 18–100 - NCT06522919RecruitingPhase 2
Immunotherapy and chemotherapy for advanced colorectal cancer
This trial tests a sequence of treatments for people with a specific type of advanced colorectal cancer (called pMMR or MSS) that has not responded to earlier therapies. Patients first receive an immunotherapy combination (pembrolizumab plus a personalized dendritic cell vaccine) followed by a chemotherapy pill (trifluridine/tipiracil) plus bevacizumab. The goal is to see if this sequence can help control the cancer.
Meldola, Forlì CesenaAges 18 years+ - NCT06529523RecruitingPhase 2
Testing tislelizumab for dMMR colorectal cancer
This trial tests the immunotherapy drug tislelizumab for people with a specific type of colorectal or rectal cancer called dMMR. It aims to see if this treatment can shrink tumors or improve outcomes in patients who haven't had many other treatments.
New York, New YorkAges 18 years+ - NCT06543836RecruitingPhase 2
Targeted therapy plus immunotherapy for advanced colorectal cancer
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06547203RecruitingPhase 2
Cetuximab, irinotecan, and toripalimab for right-sided colorectal cancer
This trial tests a combination of three drugs (cetuximab, irinotecan, and toripalimab) for people with advanced right-sided colon cancer that does not have certain gene mutations. It's for those whose cancer has gotten worse after standard treatments.
Guangzhou, GuangdongAges 18–80 - NCT06553885RecruitingPhase 2
Study of enfortumab vedotin for advanced colorectal or liver cancer
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Tampa, FloridaAges 18 years+ - NCT06555003RecruitingPhase 3
DEBIRI plus chemo vs. chemo alone for liver metastases
This trial tests if a treatment called DEBIRI (tiny beads delivering chemo directly to the liver) plus standard chemotherapy works better than chemotherapy alone for colorectal cancer that has spread to the liver and can't be fully removed by surgery.
Tehran, Tehran ProvinceAges 18 years+ - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Birmingham, AlabamaAges 18 years+ - NCT06563986RecruitingPhase 2
Combination therapy for advanced colorectal cancer in the liver
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
UtrechtAges 18 years+ - NCT06566755RecruitingPhase 3
New drug combo for a common type of colorectal cancer
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
Shenyang, LiaoningAges 18–75 - NCT06589830RecruitingPhase 2
TL938 with Trastuzumab for HER2+ Colorectal Cancer
This trial is testing a new combination of drugs (TL938 and trastuzumab) for people with a specific type of advanced colorectal cancer that is HER2-positive and RAS wild-type. It may offer a new option if you have already tried standard chemotherapy and a blood vessel-blocking drug.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07529808RecruitingPhase 1/Phase 2
New Drug BHB810 for Advanced Stomach Cancer
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Fairfax, VirginiaAges 18 years+
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic colorectal cancer?
- Yes. Clin2 currently lists 540 recruiting metastatic colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Colorectal Cancer (CRC)
- Metastatic Colorectal Cancer (mCRC)
- Unresectable Metastatic Colorectal Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Refractory Metastatic Colorectal Cancer
- MSS Metastatic Colorectal Cancer
- Microsatellite Stable Metastatic Colorectal Cancer
- Non-metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.